Adimab, LLC - 05 Aug 2021 Form 3 Insider Report for Adagio Therapeutics, Inc. (IVVD)

Role: 10%+ Owner
Signature: /s/ Philip Chase, General Counsel
Issuer symbol: IVVD
Transactions as of: 05 Aug 2021
Net transactions value: $0
Form type: 3
Filing time: 05 Aug 2021, 21:14:18 UTC
Next filing: 12 Aug 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	IVVD	Common Stock						1,985,295	05 Aug 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Date	Underlying Class	Amount	Ownership	Footnotes
holding	IVVD	Series A Preferred Stock	05 Aug 2021	Common Stock	25,000,000	Direct	F1
holding	IVVD	Series B Preferred Stock	05 Aug 2021	Common Stock	220,380	Direct	F1
holding	IVVD	Series C Preferred Stock	05 Aug 2021	Common Stock	640,320	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock is convertible at any time at the option of the holder, without payment of additional consideration, into 5 shares of Common Stock, has no expiration date and is expected to automatically convert into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

Content

Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock is convertible at any time at the option of the holder, without payment of additional consideration, into 5 shares of Common Stock, has no expiration date and is expected to automatically convert into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.